Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
EDIT: Removed press release
CategoryEurope news

EDIT: Removed press release

May 21, 2020 Off By BusinessWire

EDIT: Juvenescence put out a press release in error on May 21st, and it has been removed.

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email a link to a friend (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)

Related

TagsJuvenescence
scPharmaceuticals in pricing of public offering of common stock of about $50.0 million
Placenta Growth Factor Pipeline Review, H1 2020: Companies Involved in Therapeutics Development – ResearchAndMarkets.com

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance

July 8, 2025 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine
Go to mobile version